DailyIQ
|
Sector:HealthcareAll sectors
Last updated 5 minutes ago

GILD·Gilead Sciences, Inc.

$.
+. (+.%)
After Hours
High
$127.27
Open
$125.13
Market Cap
156.32B
52W High
$157.29
Low
$123.91
P. Close
$125.14
P/E
16.96
52W Low
$104.46
Fwd P/E
-
DailyIQ Est.
$163.49
Technical Score (1D)
27
SELL
News Sentiment
92
BULLISH
EU marketing approval for Trodelvy in breast cancer expands its indication beyond metastatic triple‑negative breast cancer, allowing the drug to be used as a first‑line monotherapy for patients ineligible for PD‑1/PD‑L1 inhibitors. The approval, based on ASCENT‑03 data showing a progression‑free‑survival benefit over chemotherapy, is expected to lift EU sales and strengthen GILD’s oncology portfolio in the coming week. In parallel, the FDA has accepted Gilead’s supplemental NDA for Yeztugo 300‑mg tablets, clearing a regulatory hurdle for a once‑weekly oral HIV pre‑exposure prophylaxis. This milestone could open a new growth engine amid a shrinking HIV treatment pipeline, adding to the company’s long‑term value narrative. Analysts note that the combination of expanded oncology indications and a forthcoming HIV prevention product may improve GILD’s earnings outlook, supporting its recent long‑term value positioning. Traders should monitor the commercial rollout timeline for Trodelvy in the EU, including pricing negotiations and reimbursement decisions that could affect early sales. Additionally, watch for the FDA’s PDUFA action date for Yeztugo and any Phase III data releases that could influence the product’s launch window. If the EU sales figures exceed expectations or the Yeztugo data are strong, the company’s cash flow and dividend policy could be reinforced, further supporting its income‑focused appeal. Finally, keep an eye on any updates from GILD’s earnings guidance that incorporate these approvals, as they will clarify the near‑term revenue trajectory.
Earnings Summary
Gilead Sciences, a biopharmaceutical firm headquartered in Foster City, California, specializes in antiviral therapies for HIV/AIDS, hepatitis, and other viral diseases, while also developing oncology and rare disease treatments. The company operates within the broader healthcare sector, specifically the drug manufacturers‑general industry, and relies heavily on its established product portfolio and pipeline collaborations to drive growth. In the most recent fiscal year, Gilead’s Q3 2025 revenue rose to $7.77 billion, a modest 2.0% increase from Q2 2025, while Q4 2025 revenue climbed to $7.93 billion, representing a 2.0% rise versus Q3 2025; this marks a deceleration from the 6.2% growth seen between Q1 and Q2 2025. EPS followed a similar pattern: Q3 2025 EPS of $2.47 beat estimates and was up 37.5% from Q2 2025’s $2.01, yet Q4 2025 EPS fell to $1.86, missing the $1.98 estimate and reflecting a 21.5% decline from Q3 2025. Across six quarters, Gilead has beaten analyst expectations in five instances, with only the Q4 2025 quarter missing, underscoring a generally strong earnings track record despite recent volatility. Historically, revenue has grown at a moderate 4–5% YoY pace, while EPS has shown more fluctuation, with a 2.1% YoY decline in Q4 2025 but an 11.8% increase in Q1 2026 versus Q1 2025, indicating a potential rebound. Recent news highlights the FDA’s acceptance of the supplemental NDA for Yeztugo, a once‑weekly oral PrEP candidate, and a 19.7‑percentage‑point jump in adjusted operating margin in Q1 2025, both of which could influence investor sentiment and future revenue mix. Investors should watch for Gilead’s next earnings guidance, particularly updates on the Yeztugo development timeline and any regulatory actions that could accelerate or delay market entry, as well as any shifts in the company’s pipeline strategy that may impact its competitive positioning in the PrEP and antiviral markets.

EPS

EstBeatMiss
$-8.59$-5.46$-2.34$0.79$3.91Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-7.14 - -
Q1'26$1.95$2.03+4.0%
Q4'25$1.98$1.86-6.2%
Q3'25$2.14$2.47+15.7%
Q2'25$1.96$2.01+2.7%
Q1'25$1.78$1.81+1.9%

Revenue

EstBeatMiss
$6.5B$6.9B$7.3B$7.7B$8.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$7.6B - -
Q1'26$7.1B$7.0B-1.3%
Q4'25$6.9B$7.9B+14.1%
Q3'25 - $7.8B -
Q2'25 - $7.1B -
Q1'25 - $6.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GILD Stock Snapshot

GILD is currently trading at $124.53, giving Gilead Sciences, Inc. a market cap of 156.32B and a P/E ratio of 17.0. Today's range spans $123.91–$127.27, with shares opening at $125.13 and moving down $0.61 (0.5%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 92/100.

Over the past year GILD has traded between $104.46 and $157.29 - the current price is +19.2% off the 52-week low and -20.8% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $157.57 (range $122.00–$180.00), implying upside of +26.5%.

Gilead Sciences, Inc. (GILD) is at $124.53 (in the lower half of its 52-week range in $104.46–$157.29), carrying a SELL signal (27/100) and bullish sentiment (92/100). The current P/E ratio stands at 17.0. The 156.32B market cap in Healthcare means this name is well-covered by analysts who can accelerate the downside through rating cuts and target reductions - a feedback loop that smaller stocks with less coverage don't face to the same degree.

When a large-cap Healthcare name with 156.32B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (92/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $124.53 (in the lower half of its 52-week range in the $104.46–$157.29 range), the structural support levels are where that sponsorship question gets answered.